If you forget cancer and disregard GVHD, Nash, mon

If you forget cancer and disregard GVHD, Nash, monotherapy and just focus on combo which we are submitting the BLA for in September (possibly) - There are 230,000 class two and three resistant HIV patients if we only got 10% that is 23,000 patients times $35,000 a patient gives you $805 million revenue at 10 times revenue that puts the value of the company at well over $10 a share.